FDA Approves Restylane Lyft for Chin Augmentation in Adults
Key Takeaways
Restylane Lyft received FDA approval for chin augmentation in adults with mild-to-moderate chin retrusion.
Trial data showed sustained improvement and high patient satisfaction at 12 months.
Galderma announced today that the U.S. Food and Drug Administration (FDA) has approved Restylane® Lyft™with Lidocaine for chin augmentation in adults over 21 with mild-to-moderate chin retrusion.
The approval is supported by pivotal trial data showing high efficacy and durable results, according to a news release from Galderma. At 3 months post-injection, 99.1% of investigators and 94.4% of patients reported visible chin improvement. At 12 months, satisfaction was high (95.5% of investigators and 89.0% of patients reporting aesthetic benefit), and 86.3% of participants said the filler provided natural-looking projection and improved overall chin-to-jawline contour. The approval makes Restylane Lyft the only hyaluronic acid (HA) filler in the U.S. indicated for use in the midface, facial folds, hands, and now the chin.
Restylane Lyft uses Galderma’s proprietary NASHA® technology and is characterized by a high G-prime, making it particularly suitable for structural support in the lower face. Its firm gel consistency allows for precise shaping and projection in the chin area. The formulation is backed by more than two decades of global safety data and over 77 million aesthetic treatments worldwide.
“The chin plays a vital role in overall facial harmony," said Alia S. Brown, MD, FAAD, of the Atlanta Biomedical Clinical Research and Georgia Dermatology Partners, said in the press release. "Restylane Lyft offers a safe and effective way to enhance this area, helping to bring balance and definition to the face. It’s already a trusted product in my clinic, supported by my own experience and over two decades of global safety data, so I’m pleased to now be able to also offer patients its benefits in the chin.”
No serious or unexpected adverse events were reported during the trial. The most common side effects included bruising, edema, and tenderness at the injection site.
Source: Galderma press release. November 5, 2025.